{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Estimated by the average visual acuity amongst patients evaluated with a 95% confidence interval.","groups":[{"description":"Patients will receive 1 intra-arterial injection (IA) of melphalan every 21- 30 days. Injections may be repeated every 21-30 days (up to a maximum of 3 cycles) assuming the patients meets the criteria to begin the next cycle.","id":"OG000","title":"Melphalan"}],"populationDescription":"The study was terminated at stage I since the therapy was considered not feasible to deliver.\n\nNo patients had this data available. Patients either had affected eye enucleated, or did not complete protocol therapy.","reportingStatus":"POSTED","timeFrame":"1 year after therapy","title":"Vision Acuity, Assessed According to the Amblyopia Treatment Study Visual Acuity Testing Protocol","type":"SECONDARY"}